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BLOOD IN 131I THERAPY FOR DIFFERENTIATED THYROID CARCINOMA
Leila Fatholahi,* Faraj Tabeie,* Ali Mahmoud Pashazadeh,† Hamid Javadi,‡
Majid Assadi,† and Isa Neshandar Asli*Abstract—The amount of 131I necessary for successful ablation
in patients with differentiated thyroid cancer (DTC) is still sub-
ject to debate. This study investigates the relationship of the
absorbed dose of radiation to the blood while administering
131I activity with several other parameters in DTC patients.
This prospective study included 90 DTC patients who were
classified into three groups according to their level of dosage:
3.7 GBq (38.9%), 5.55 GBq (55.6%), and 7.4 GBq (5.5%).
Blood dosimetry of treated patients was performed using ex-
ternal whole-body counting with a Geiger Muller dosimeter
located 2 m away from the patients. Dose rate was measured
at 2, 4, 5, 24, and 48 h after the administration of radioiodine.
Based on the results of whole-body dose rate measurements,
48 h after administration of 3.7, 5.55, and 7.4 GBq of radio-
iodine, absorbed doses to patients’ blood were estimated at 0.49 ±
0.12, 0.71 ± 0.21, and 0.76 ± 0.11 Gy, respectively. Increasing radio-
iodine dosage from 3.7 GBq to 5.55 GBq significantly increased
blood dose, while there was no significant difference in blood dose
between radioiodine dosages of 5.55 GBq and 7.4 GBq. The ab-
sorbed dose to the blood was significantly correlated to the pa-
tients’ gender and the presence of lymph node metastases, but
it was not significantly correlated to the type of pathology and
regional or distant metastases. Ablation activities exceeding
5.55 GBq produce no further increase in the accumulated activ-
ity per volume of blood. The literature regarding this issue is
scarce, and further studies are required to verify these prelimi-
nary results.
Health Phys. 108(1):53–58; 2015
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EACH YEAR, 26,000 patients in the United States and 1,500
in the United Kingdom are diagnosed with thyroid-related
cancers (Hackshaw et al. 2007). The reports reveal that the
rate of differentiated thyroid cancers (DTC) has increased
40% in the United States from 2000 to 2005 (Azizmohammadi
et al. 2013; Hackshaw et al. 2007). DTC is the most common
subcategory of thyroid cancer. Thirty percent of patients
suffer from recurrence of the disease.
Routine treatment strategy for DTC consists of a total
thyroidectomy followed by radiation therapy with radioio-
dine to ablate remaining thyroid tissue (Verburg et al.
2011). According to recent research, DTC therapy combin-
ing surgery with radioiodine ablation is usually associated
with a 10‐y survival for 90% of patients (Hackshaw et al.
2007). Radioiodine ablation for DTC patients matters for
the following reasons. First, the presence of remnant thy-
roid tissue after surgery makes it difficult to detect and treat
regional or distant metastases (Miccoli et al. 1998; Van
Nostrand et al. 2002). Second, thyroid cancers typically
tend to be multifocal, so residual thyroid tissue will more
likely include malignant cells. Third, poorly differentiated
thyroid cancers can become anaplastic carcinoma. In all
cases, radioiodine ablates malignant and metastatic cells
that escaped the surgery, reducing the risk of recurrence
(Henkin et al. 2006). Because this therapy is well known
as an effective method to treat DTC, it has become an in-
ternationally standard approach (Dietlein et al. 2007; Gharib
et al. 2010; Hanscheid et al. 2006; Luster et al. 2008).
After a patient is treated with radioiodine, an important
following step is the attempt to determine the dose that is
absorbed in lesion. Up to now, several techniques have been
established in this regard. One of the first approaches used
for dosimetry of patients after radioiodine thyroid therapy
was a method introduced by Benua et al. (1962) that has
provided a way to calculate the limited dose to blood that
can be tolerated and also the dose to the lesion per unit of
administered activity. The procedure describes that the max-
imum amount of administered activity to a patient can be53
ed reproduction of this article is prohibited.
54 Health Physics January 2015, Volume 108, Number 1defined as the amount of activity that leads to an absorbed
dose to blood of 2 Gy. Later, this method was developed
by Furhang et al. (2002), in which some parameters were
fitted to patients’ clearance data to provide a dosimetry al-
gorithm. In recent years, Hanscheid et al. (2006) set up do-
simetric procedures in which the need for blood sampling
to determine patient absorbed dose has been eliminated.
One important, if controversial, aspect of radioiodine
ablation is determining the standard amount of radioiodine
activity required for an optimally successful ablation. Past
trials have associated values ranging from 0.99 GBq to
3.7 GBq, with favorable outcomes in the ablation of remain-
ing tissue in newly diagnosedDTC cases (Sawka et al. 2008).
Higher dosages are recommended for metastatic cases, but
these can cause serious complications affecting bone marrow
and healthy tissues, so activity values are limited to around
7.4 GBq (Lassmann et al. 2010; Zakani et al. 2011). On the
other hand, while higher doses of radioiodine increase suc-
cess rates, some studies discovered no further improvement
in ablation success for amounts higher than 1.85 GBq (Bal
et al. 2004; Hackshaw et al. 2007). While the optimal amount
of radioiodine remains subject to debate, a study showed that
the absorbed dose to the blood is a more useful predictor of
ablation success in thyroid cancer patients than the amount
of administered radioiodine (Verburg et al. 2011).
Therefore, the current study investigates whether in-
creasing the administered radioiodine, which may increase
complications, would necessarily increase its absorbed dose
to the blood. It also correlates absorbed dose to the blood
with patients’ gender, age, type of pathology (PTC or pap-
illary thyroid carcinoma and FTC or follicular thyroid car-
cinoma), and whether metastases are in the lymph node,
regional, or distant.METHODS AND MATERIALS
Ninety (90) DTC patients were included in this study.
The necessary histological information was obtained from
patients’ documents. No patients were excluded for any
reasons due to their gender, age, or pathology.
All patients underwent external whole-body counting
to measure the absorbed dose to the blood of the DTC pa-
tients after radioiodine ablation. This method of blood do-
simetry, which does not require blood sampling, is based
on the fact that 14% of the whole-body residence time is
attributed to the blood (Hanscheid et al. 2006). Following
treatment, patients were stratified into three groups who
were administered 3.7 GBq (38.9%), 5.55 GBq (55.6%),
and 7.4 GBq (5.5%); then external whole-body counting
of each patient was performed by a Geiger Muller dosim-
eter. During whole-body counting, the dosimeter was lo-
cated 1 m above ground level at a distance of 2 m behindwww.health-phy
Copyright © 2014 Health Physics Society. Unauthoeach patient. The first measurement was performed ap-
proximately 2 h after radioiodine administration, with fur-
ther measurements following at 4, 5, 24, and 48 h. An
exponential decay curve was fitted to the dose measure-
ments to obtain a 48‐h whole-body radioiodine dose-rate
curve for each patient.
The following formula, recently published by Hanscheid
et al. (2009), calculated absorbed dose to the blood per unit
of administered radioactivity (Dblood/A0) using dose-rate
curve data:
Dblood
A0
mGy=MBqð Þ¼ − 15:12
BLV mLð Þ þ
0:0188
wt kgð Þ½ 2=3
 !
 t hð Þ
1n R tð Þ½  :
BLV is the individual blood volume estimated from the
patient’s weight (wt) and height (ht) according to the
equation proposed by Retzlaff et al. (1969):
BLV ¼ 31:9 htþ 26:3 wt - 2402 for male
BLV ¼ 56:9 htþ 14:1 wt - 6460 for female;
R(t) is radioiodine retention at time t, and t(h) is the time
after radioiodine injection. The ANOVA test and indepen-
dent t-test compared the various parameters. The correlation
of absorbed dose to the blood with administered activity of
radioiodine, gender, age, type of pathology, and lymph node,
regional, or distant metastases was considered statistically
significant at p < 0.05.RESULTS
All 90 adult patients enrolled in this study had been
newly diagnosed with DTC and recently underwent total
or near-total thyroidectomies: 26 were men (28.9%) and
64 were women (71.1%); five (5.6%) patients had folli-
cular cancer, 85 (94.4%) patients had papillary cancer,
46 (51.1%) patients had metastases in the lymph node,
40 (44.4%) patients had regional metastases, and nine
(10%) patients had distant metastases. Mean (±SD) of the
patients’ age, height, and weight were 42.88 (±16.43) y,
158.49 (±8.66) cm, and 69.62 (±10.61) kg, respectively.
Based on their height and weight, patients’ individual
blood volume was estimated at 5,197.90 ± 176.34 mL for
men and 3,165.95 ± 121.79 mL for women.
Results of dose rate measurements by Geiger Muller
dosimeter at various times were used to draw a 48‐h dose-
rate curve. Fig. 1 presents such curves following adminis-
tration of 3.7, 5.55, and 7.4 GBq of radioiodine.
Based on Hanscheid’s equation and using data of
BLV and retention measurement, which was calculated
by normalization of the last measurement (48 h aftersics.com
rized reproduction of this article is prohibited.
Fig. 1. 48‐h dose-rate curves following administration of 3.7 GBq
(diamond), 5.55 GBq (rectangle), and 7.4GBq (triangle) of radioiodine.
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55Blood dose in DTC c L. FATHOLAHI ET AL.administration of radioiodine) to the initial measurement
(2 h after administration of radioiodine) of dose rates, ab-
sorbed dose to the blood of patients was determined as
0.49 ± 0.12, 0.71 ± 0.21, and 0.76 ± 0.11 Gy for administra-
tion of 3.7, 5.55, and 7.4 GBq of radioiodine, respectively.
Statistical analysis of data revealed that increasing the
radioiodine dose from 3.7 GBq to 5.55 GBq significantly
increases the absorbed dose to the blood of patients, while
no significant difference was observed between patients
who received doses of 5.55 GBq and 7.4 GBq.
Table 1 presents the mean (±SD) values of absorbed
dose to the blood 48 h after radioiodine administration,
broken down by gender, type of pathology, presence of
residual thyroid tissue after thyroidectomy, and whether
there were lymph node, regional, or distant metastases.
The mean absorbed dose to the blood in male and fe-
male subgroups was estimated to be 0.53 ± 0.14 Gy and
0.66 ± 0.21 Gy, respectively. The difference between these
two groups was statistically significant (p = 0.026).
Regarding the type of pathology, absorbed dose to the
blood was estimated at 0.62 ± 0.20 and 0.66 ± 0.20 Gy for
patients with PTC and with FTC, respectively. The differ-
ence between these groups was not statistically significant
(p = 0.951).
Analysis of absorbed dose to the blood in patients
with (0.62 ± 0.22 Gy) and without (0.63 ± 0.15 Gy) residual
thyroid tissue after thyroidectomy revealed no difference
between these two groups (p = 0.115).
Also, the median absorbed dose to the blood in patients
with lymph node metastases was estimated to be 0.67 ±
0.23 and 0.58 ± 0.17 Gy without. The difference between
these two groups was statistically significant (p = 0.036).
The median absorbed dose to the blood for patients
with regional metastases was 0.64 ± 0.18 and 0.61 ±
0.22 Gy without. The observed difference was not signif-
icant (p = 0.586).
Finally, the absorbed dose to the blood in patients with
distant metastases was estimated at 0.72 ± 0.12 Gy and at
0.62 ± 0.21 Gy without. Statistical analysis of data revealed
no significant difference in absorbed dose to the blood be-
tween the two groups (p = 0.155).www.health-physics.com
Copyright © 2014 Health Physics Society. Unauthorized reproduction of this article is prohibited.
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In recommended protocols for DTC therapy, radio-
iodine ablation has long been associated with a lower rate
of recurrence and distant metastases, as well as a reduced
risk of cancer mortality, than undergoing only surgery
(DeGroot et al. 1990; Massin et al. 1984; Mazzaferri 1997;
Schlumberger 1998; Simpson et al. 1988; Tsang et al. 1998).
While some physicians favor low radioiodine levels
approximating 1.11 GBq, others prefer higher amounts of
up to 7.4 GBq (Beierwaltes 1987; Hay et al. 2002; Ramanna
et al. 1985). Furthermore, because of some technical diffi-
culties, physicians in most centers often use a predeter-
mined and fixed radioiodine level from 1.11 to 7.4 GBq
rather than techniques based on bio-kinetic properties of
patients (Bal et al. 2004).
The British Thyroid Association guidelines, specifi-
cally, recommend radioiodine ablation after a total thy-
roidectomy for DTC patients with tumors larger than
1 cm. While there is no agreement on the standard amount
of radioiodine, an ablation dose of 3.7 GBq is usual, even
though some centers prefer ablation doses as low as 1.11
GBq (Watkinson et al. 2004).
The European consensus report on ablation recom-
mends activity of 3.7 GBq for those DTC patients with a
high risk of recurrence, distant metastases, or incomplete
tumor resection (Pacini et al. 2005).
From a historical point of view, it has long been ac-
cepted that a single administration of a higher radioiodine
level results in a more successful ablation. This was based
on the hypothesis that the larger the amount of radioiodine,
the more likely it is than lower levels to ablate remnants and
destroy residual micro-metastases (Beierwaltes et al. 1984).
A study by Mazzaferri of 30‐y recurrence rates of
DTC patients treated with radioiodine ablation after their
thyroidectomies found no significant difference between
low-dose (1 to 1.85 GBq) and high-dose (1.89 to 7.4 GBq)
groups (Mazzaferri 1997).
One benefit of lower radioiodine dosage is smoother
outpatient treatment, because it reduces the radiation ex-
posure to the patient’s environment and household mem-
bers. As well, lower dosage also lowers financial cost,
lessens the amount of time a patient spends in isolation,
shortens hospital stays, and lowers whole-body irradia-
tion (DeGroot et al. 1990; Grigsby et al. 2000). Further-
more, because the risk of a second primary malignancy
is correlated with radioiodine ablation, a lower dose re-
duces this risk (Rubino et al. 2003).
While this study kept the amount of administered
radioiodine relatively low, the authors evaluated whether
higher doses would necessarily increase the absorbed dose
to the blood. This study revealed that absorbed dose to the
blood of patients with DTC administered with 5.55 GBqwww.health-phy
Copyright © 2014 Health Physics Society. Unauthoof radioiodine is significantly higher than that of patients
administered with 3.7 GBq of radioiodine. However,
there is no significant difference in the absorbed dose to
patients’ blood when treated with 7.4 GBq of radioiodine
compared to 5.55 GBq. Given that the absorbed dose to
the blood is a better predictor of ablation success than over-
all radioiodine administered (Verburg et al. 2011), these
findings suggest that 5.55 GBq would be the most favor-
able dose compared to 3.7 GBq and 7.4 GBq of radioiodine
in thyroid ablation. Dosage of 5.55 GBq is not only more
advantageous therapeutically, but it also causes fewer thera-
peutic problems than a dose of 7.4 GBq.
These findings contrast the results of Mazzaferri on
1,004 DTC patients undergoing radioiodine ablation of
thyroid remnant. That study categorized patients into two
groups: those treated with 1–1.85 GBq (mean 1.74 GBq)
of radioiodine and those treated with 1.89–7.4 GBq (mean
4.1 GBq). That study observed no significant difference
in recurrence rates between the two groups of patients
(Mazzaferri 1997). One possible reason for this is that
the current study used different values of radioiodine ac-
tivity in the ablations. The Mazzaferri study patients were
administered various amounts of radioiodine ranging from
1 GBq to 7.4 GBq, which made it impossible to assess the
effect of each dose on the ablation’s overall success. As
well, because that analysis used only two dose groups of
less than and greater than 1.85 GBq, the current study was
more nuanced, dividing patients into three dose groups of
3.7, 5.55, and 7.4 GBq.
The authors observed that the absorbed dose to the
blood in female patients is significantly higher than in
male patients. As well, absorbed dose to the blood is signif-
icantly higher in patients with lymph node metastases than
without. This study also indicates that there is no correlation
between absorbed dose to the blood and whether a patient
has PTC or FTC pathology or regional or distant metastases.
One of the main problems in this study was related
to measuring whole-body dosage using a Geiger Muller
dosimeter in which the operator was exposed to radioiodine.
In most advanced nuclear medicine centers, dosimeter sys-
tems are launched 2 m above the patient’s coach to record
external whole-body radiation.
This study suffered from a shortage of patients under-
going a 7.4 GBq radioiodine dosage and a small overall
sample of participating patients compared to other studies.
Therefore, further research requires a larger number of
patients split into more categories of radioiodine dosages
to find the optimum activity for the best therapeutic abla-
tion outcomes.
CONCLUSION
There is no further increase in the overall activity per
volume of blood when radioiodine ablation dosages exceedsics.com
rized reproduction of this article is prohibited.
57Blood dose in DTC c L. FATHOLAHI ET AL.5.55 GBq. The literature on this issue remains scarce, and
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